Your browser doesn't support javascript.
loading
Altered skeletal muscle glucose-fatty acid flux in amyotrophic lateral sclerosis.
Steyn, Frederik J; Li, Rui; Kirk, Siobhan E; Tefera, Tesfaye W; Xie, Teresa Y; Tracey, Timothy J; Kelk, Dean; Wimberger, Elyse; Garton, Fleur C; Roberts, Llion; Chapman, Sarah E; Coombes, Jeff S; Leevy, W Matthew; Ferri, Alberto; Valle, Cristiana; René, Frédérique; Loeffler, Jean-Philippe; McCombe, Pamela A; Henderson, Robert D; Ngo, Shyuan T.
Afiliação
  • Steyn FJ; School of Biomedical Sciences, The University of Queensland, St Lucia, Brisbane 4072, Australia.
  • Li R; Centre for Clinical Research, The University of Queensland, Herston, Brisbane 4029, Australia.
  • Kirk SE; Department of Neurology, Royal Brisbane & Women's Hospital, Brisbane 4029, Australia.
  • Tefera TW; Wesley Medical Research, Level 8 East Wing, The Wesley Hospital, Auchenflower 4066, Australia.
  • Xie TY; School of Biomedical Sciences, The University of Queensland, St Lucia, Brisbane 4072, Australia.
  • Tracey TJ; The Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, Brisbane 4072, Australia.
  • Kelk D; The Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, Brisbane 4072, Australia.
  • Wimberger E; The Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, Brisbane 4072, Australia.
  • Garton FC; School of Biomedical Sciences, The University of Queensland, St Lucia, Brisbane 4072, Australia.
  • Roberts L; The Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, Brisbane 4072, Australia.
  • Chapman SE; The Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, Brisbane 4072, Australia.
  • Coombes JS; The Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, Brisbane 4072, Australia.
  • Leevy WM; Institute for Molecular Bioscience, The University of Queensland, St Lucia, Brisbane 4072, Australia.
  • Ferri A; School of Human Movements and Nutrition Sciences, The University of Queensland, St Lucia, Brisbane 4072, Australia.
  • Valle C; School of Allied Health Sciences, Griffith University, Southport, Gold Coast 4222, Australia.
  • René F; Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556, USA.
  • Loeffler JP; School of Human Movements and Nutrition Sciences, The University of Queensland, St Lucia, Brisbane 4072, Australia.
  • McCombe PA; Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556, USA.
  • Henderson RD; IRCCS Fondazione Santa Lucia, Rome, Italy.
  • Ngo ST; National Research Council, Institute of Translational Pharmacology (IFT), Rome, Italy.
Brain Commun ; 2(2): fcaa154, 2020.
Article em En | MEDLINE | ID: mdl-33241210
Amyotrophic lateral sclerosis is characterized by the degeneration of upper and lower motor neurons, yet an increasing number of studies in both mouse models and patients with amyotrophic lateral sclerosis suggest that altered metabolic homeostasis is also a feature of disease. Pre-clinical and clinical studies have shown that modulation of energy balance can be beneficial in amyotrophic lateral sclerosis. However, the capacity to target specific metabolic pathways or mechanisms requires detailed understanding of metabolic dysregulation in amyotrophic lateral sclerosis. Here, using the superoxide dismutase 1, glycine to alanine substitution at amino acid 93 (SOD1G93A) mouse model of amyotrophic lateral sclerosis, we demonstrate that an increase in whole-body metabolism occurs at a time when glycolytic muscle exhibits an increased dependence on fatty acid oxidation. Using myotubes derived from muscle of amyotrophic lateral sclerosis patients, we also show that increased dependence on fatty acid oxidation is associated with increased whole-body energy expenditure. In the present study, increased fatty acid oxidation was associated with slower disease progression. However, within the patient cohort, there was considerable heterogeneity in whole-body metabolism and fuel oxidation profiles. Thus, future studies that decipher specific metabolic changes at an individual patient level are essential for the development of treatments that aim to target metabolic pathways in amyotrophic lateral sclerosis.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article